Is PT-141 (Bremelanotide) Legal in South Carolina? How to Access It Legally
HealthRX.com
South Carolina rules for PT-141 are not clearly stated
Key numbers
- 1.75 mgStrength of the single FDA-approved Vyleesi injection, which is prescription onlySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Vyleesi patients reporting nausea in trials (placebo: 1.3%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesMinimum wait before anticipated sexual activity under label dosingSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximal systolic blood pressure rise per dose (diastolic: 3 mmHg)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- FDA status / Bremelanotide is approved as Vyleesi, NDA 210557, original approval June 21, 2019 [2][3]
- Form / 1.75 mg subcutaneous autoinjector, prescription only [2]
- Approved use / Acquired, generalized HSDD in premenopausal women [2]
- Not approved for / Men, postmenopausal women, or enhancing sexual performance [2]
- Compounded or research-use PT-141 / Not Vyleesi, not FDA-approved drugs [2][4]
- Boxed warning / None, and no REMS in the label or 2019 approval letter [2][3]
- South Carolina / Board of Medical Examiners website lists a notice on research-grade and FDA-ineligible peptides [1]
What is the FDA-approved bremelanotide product?
Bremelanotide is approved as Vyleesi under NDA 210557, originally approved June 21, 2019, now held by Cosette Pharmaceuticals [2][3]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only [2].
The approved use is premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [2]. Acquired means it developed in a woman who previously had no problem; generalized means it occurs regardless of stimulation, situation or partner [2]. The label states that Vyleesi is not indicated for HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance [2].
What about PT-141 sold as a compounded or research-use peptide?
PT-141 products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [2][4].
Bremelanotide does not appear on FDA's page of bulk substances that may raise significant safety risks when compounded (content dated 04/22/2026), or in any category on FDA's bulk-substance lists, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5][6][7]. Absence from those lists is not an approval.
What does the South Carolina Board page show?
The Board of Medical Examiners website lists a notice concerning the prescribing of research-grade peptides and FDA-ineligible peptides [1]. The page gives only the notice's title, not its requirements, so what the notice requires is not stated here [1].
Questions worth asking
What does the Vyleesi label say to watch for?
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended for patients at high risk of cardiovascular disease [2]. Each dose transiently raises blood pressure and lowers heart rate: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute, and values usually returning to baseline within 12 hours [2]. In an open-label ambulatory blood pressure study of 127 premenopausal women dosed daily for 8 days, mean daytime increases were 1.9 mmHg systolic and 1.7 mmHg diastolic [2].
Focal hyperpigmentation of the face, gums or breasts was reported by 1% of patients in the placebo-controlled trials versus none on placebo, and was more likely in patients with darker skin and with daily dosing; the label says to consider discontinuing if it develops [2]. Nausea was reported by 40.0% of Vyleesi patients versus 1.3% on placebo; 13% needed anti-nausea medicine and 8% discontinued the trials because of it [2].
The label says Vyleesi may slow stomach emptying and reduce absorption of oral medicines. It says to avoid Vyleesi with oral drugs that depend on threshold blood levels, such as antibiotics, and to consider skipping Vyleesi when a quick effect of an oral medicine such as indomethacin is wanted [2]. It also says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction, because Vyleesi may significantly decrease naltrexone exposure [2].
Label dosing: 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and more than 8 doses per month is not recommended [2].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 legal in South Carolina?
Do I need a prescription for bremelanotide?
Is compounded bremelanotide approved?
What is Vyleesi approved to treat?
How is Vyleesi used?
References
Show all 7 referencesHide references
- SCLLR. SCLLR
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.